ORRs of 54.8% and 50.0% achieved in locally advanced and metastatic cSCC, with median follow-up durations of 24.1 and 29.3 months, respectively. Results demonstrate a deepening of response over time, ...

Combining retifanlimab (Zynyz) with standard-of-care chemotherapy significantly improved progression-free survival (PFS) in ...

The Skin Cancer Foundation’s “Destination Healthy Skin” program has made a stop in Morgantown to provide free skin cancer ...

A common immunotherapy approach helped stave off disease progression in patients with a form of anal cancer that is caused by ...

Scott and I would like to thank Rensseaerville and the Hilltowners that have collectively come together to show love and compassion for Scott during his arduous journey with squamous cell carcinoma of ...

Immune checkpoint inhibitors are the superheroes of cancer therapy. | Immune checkpoint inhibitors are the superheroes of ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Inavolisib showed promise in treating patients with PIK3CA-mutated solid tumors, demonstrating favorable safety and disease ...

Retifanlimab improved upon standard chemotherapy in patients with locally recurrent or metastatic anal cancer in a phase 3 ...

Rachel Allbaugh, DVM, MS, DACVO, summarizes some of the recent advancements avialble for treating and managing this disease ...

New study shows that AI can predict lung cancer from digitized patient tissue samples rapidly and with a high degree of ...